RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
June 13 2021 - 4:00PM
RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage,
immunology-based biopharmaceutical company focused on
discovering, developing and commercializing oral small molecule
therapies for patients with significant unmet needs in oncology and
inflammatory diseases, today announced that the Company plans to
report top line data from its Phase 1b clinical trial of RPT193 in
patients with moderate to severe atopic dermatitis (AD) in a
premarket press release and webcast on Monday, June 14, 2021.
RAPT will host a conference call accompanied by a slide
presentation at 8:30 a.m. ET on Monday, June 14th. The live webcast
and audio archive of the presentation may be accessed on the RAPT
Therapeutics website at
https://investors.rapt.com/events-and-presentations. The call can
be accessed by dialing (833) 672-0665 (domestic) or (929) 517-0344
(international) and referring to conference ID 4696044. The webcast
will be available for replay for 30 days. Please connect to the
website 10 minutes prior to the presentation to ensure adequate
time for any software downloads that may be necessary to listen to
the webcast.
About RAPT Therapeutics, Inc.RAPT
Therapeutics is a clinical stage immunology-based biopharmaceutical
company focused on discovering, developing and commercializing oral
small molecule therapies for patients with significant unmet needs
in oncology and inflammatory diseases. Utilizing its proprietary
discovery and development engine, the Company is developing highly
selective small molecules designed to modulate the critical immune
drivers underlying these diseases. RAPT has discovered and advanced
two unique drug candidates, FLX475 and RPT193, each targeting C-C
motif chemokine receptor 4 (CCR4), for the treatment of cancer and
inflammation, respectively. The Company is also pursuing a range of
targets that are in the discovery stage of development.
RAPT Media Contact:Aljanae
Reynoldsareynolds@wheelhouselsa.com
RAPT Investor Contact:Sylvia
Wheelerswheeler@wheelhouselsa.com
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
RAPT Therapeutics (NASDAQ:RAPT)
Historical Stock Chart
From Apr 2023 to Apr 2024